Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study reveals hidden blood risk in common arthritis drugs

NCT ID NCT07237906

Knowledge-focused Sponsor: Burak Ugur Cetin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviewed medical records of 122 adults who took TNF-α inhibitors (drugs for rheumatoid arthritis and similar conditions) to find out how often they developed neutropenia—a drop in infection-fighting white blood cells. Researchers looked at blood test results and patient histories to determine the frequency, severity, and risk factors for this side effect. The goal was to better understand the real-world impact of these widely used medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

122 people

The number who actually took part.

Started

Sep 2023

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with inflammatory arthritis who were treated with TNF-α inhibitor therapy at the Physical Medicine and Rehabilitation Department of Istanbul University-Cerrahpasa, a tertiary care center in Istanbul, Turkey, between September 2023 and January 2025.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Initiation of TNF-alpha inhibitor therapy at least once in our clinic between September 2023 and January 2025 * Age 18 years or older * At least one complete blood count performed during the follow-up period * Availability of complete clinical and laboratory data in the hospital's electronic medical records or patient files Exclusion Criteria: * History of other hematologic disorders that may contribute to the development of neutropenia (e.g., aplastic anemia, leukemia, myelodysplastic syndrome) * Concurrent treatment with cytotoxic chemotherapy or immunosuppressive agents (e.g., azathioprine, cyclophosphamide) * Insufficient follow-up duration or incomplete laboratory data that precluded adequate evaluation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neutropenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

arthritic joint disease Drug-Related Side Effects and Adverse Reactions neutropenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neutropenia TNF-alpha inhibitors

Contacts and locations

Locations

  • Istanbul University - Cerrahpasa (IUC)

    Istanbul, 34098, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.